Psychedelics could make mental health worse in individuals with a personality disorder

The interest in psychedelics is growing each in scientific circles and amongst the general public. These are powerful substances able to altering perception, mood and various mental processes. They also show promise for treating a wide selection of mental health disorders.

However, for his or her use to be secure and effective, it’s necessary to grasp how they interact with different mental health conditions. This is very true for personality disorders.

A personality disorder is a sort of mental disorder involving rigid and unhealthy patterns of pondering, functioning and behaving, which significantly affect an individual’s life. Understanding their interaction with psychedelics is crucial. These substances can deeply influence mental states. They can worsen or improve symptoms in ways unique to those disorders.

In a recent studyresearchers at Imperial College London investigated the complex relationship between psychedelics and mental health, highlighting the potential risks for individuals with personality disorders.

The study collected self-reported data from 807 individuals who used psychedelics in various settings, from recreational to therapeutic. They measured participants’ mental wellbeing before and after using psychedelics using a scale called the Warwick-Edinburgh mental wellbeing scale. The researchers considered it a meaningful drop in mental health if someone’s happiness and wellbeing fell greater than what was typical for most individuals within the study.

The researchers specifically checked out those that had negative experiences while on psychedelics. They found that only 16% of all participants reported an overall negative response. But a good portion of those negative experiences (31%) were reported by individuals with a history of personality disorders.

However, the study has several limitations, including the reliance on self-reported data, the small variety of participants and a 56% dropout rate. All of those aspects would have skewed the outcomes.

Other limitations include the dearth of a control group (people given a placebo or standard treatment) for comparison. Additionally, there have been variations in the kinds and dosages of psychedelics used.

The study’s approach to participant selection could also result in biased results. And lumping different personality disorders together might overlook specific risks related to each.

Different responses

Various personality disorders might respond otherwise to psychedelics. For instance, individuals with histrionic personality disorder (excessive attention-seeking and emotional overreaction) or borderline personality disorder (emotional instability, intense relationships and fear of abandonment) might feel worse or more unstable.

And those with schizotypal personality disorder (social anxiety, odd beliefs and eccentric behaviour) could develop into more paranoid.

People with narcissistic personality disorder (excessive self-importance, lack of empathy, and wish for admiration) may struggle with the self-reflective nature of psychedelics because they often have a tough time handling criticism.

Considering the study’s notable limitations, we must approach its findings with some scepticism. Yet the study does recognise the potential advantages of psychedelics for mental health, stressing the necessity for careful screening for personality disorders.

Using psychedelics safely and effectively requires a personalised approach. This is very true for vulnerable people. This highlights the importance of refining psychedelic therapy to make it secure and effective for all.

As we explore the expanding territory of psychedelic therapy, it’s vital to grasp how these substances interact with mental health conditions – including personality disorders.

We must use more rigorous methods, equivalent to controlled trials to check psychedelics to straightforward treatments or a placebo. Personality disorders also needs to be verified via skilled evaluation, not only self-reports. And, finally, psychedelic doses must be uniform with the intention to reliably assess their therapeutic effect.